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Abstract
TNF is a central actor during inflammation and a well-recognized
drug target for inflammatory diseases. We found that the mouse
strain SPRET/Ei, known for extreme and dominant resistance
against TNF-induced shock, displays weak expression of TNF recep-
tor 1 protein (TNFR1) but normal mRNA expression, a trait geneti-
cally linked to the major TNFR1 coding gene Tnfrsf1a and to a
locus harbouring the predicted TNFR1-regulating miR-511. This
miRNA is a genuine TNFR1 regulator in cells. In mice, overexpres-
sion of miR-511 down-regulates TNFR1 and protects against TNF,
while anti-miR-511 up-regulates TNFR1 and sensitizes for TNF,
breaking the resistance of SPRET/Ei. We found that miR-511 inhibits
endotoxemia and experimental hepatitis and that this miR is
strongly induced by glucocorticoids and is a true TNFR1 modulator
and thus an anti-inflammatory miR. Since minimal reductions of
TNFR1 have considerable effects on TNF sensitivity, we believe
that at least part of the anti-inflammatory effects of glucocorti-
coids are mediated by induction of this miR, resulting in reduced
TNFR1 expression.
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Introduction
Acute systemic inflammation is a hallmark of many severe
conditions, such as sepsis, severe burns, haemorrhage, ischaemia/
reperfusion and others. Although this inflammation serves to remove
invading micro-organisms and to restore homeostasis, an unbal-
anced regulation of the response causes systemic inflammatory
response syndrome (SIRS), which is often fatal. SIRS is coordinated
by a few powerful pro-inflammatory cytokines, including tumour
necrosis factor (TNF). TNF activates the expression of many genes
involved in cytokine production, leucocyte infiltration, blood pres-
sure reduction and coagulation. It also induces cell death and wound
healing and is involved in antibacterial immunity (Puimege et al,
2014; Van Hauwermeiren et al, 2011). TNF injection in mammals is
a validated model system because TNF injection of microgram doses
causes a lethal systemic inflammation, which is mediated by several
secondary cytokines, such as interleukin-1 (IL-1), IL-17 and interfer-
ons, so inhibition of these cytokines leads to some protection against
TNF (Huys et al, 2009; Takahashi et al, 2008). TNF binds two recep-
tors, TNFR1 and TNFR2, the former of which is constitutively
expressed on most cells, while the latter is inducible and has a more
restricted expression pattern. The major activities of TNF (induction
of inflammation and cell death) are mediated by TNFR1, while TNF’s
immune-regulatory effects, for example on regulatory T cells, DC
subtypes and myeloid-derived suppressor cells, are mediated by
TNFR2 (Okubo et al, 2013; Zhao et al, 2012). Anti-TNF therapy,
which is used for inflammatory bowel diseases, rheumatoid arthritis
and psoriasis, limits both TNFR1 and TNFR2 signals. Therefore, part
of the side effects of anti-TNF therapies (e.g. appearance of psoriatic-
like lesions) might be prevented by selective inhibition of TNFR1
(Van Hauwermeiren et al, 2011). We recently demonstrated that
TNFR1 is an interesting drug target by showing that reducing TNFR1
expression by 50% (TNFR1+/ mice) led to total protection against
TNF-induced SIRS and TNF-induced intestinal barrier dysfunction
(Van Hauwermeiren et al, 2013, 2014).
The search for new therapeutic targets for SIRS and other TNF-
mediated diseases should include investigation of the poorly under-
stood regulation of the TNFR1 coding gene (Tnfrsf1a), located on
distal chromosome 6 in the mouse genome (Puimege et al, 2014).
The absence of canonical TATA and CCAAT boxes and the high GC
content have been associated with the promoters of housekeeping
genes (Kemper & Wallach, 1993). However, functional binding
sites for C/EBP (Bristol et al, 2009) and NF-jB (Baxter et al, 2006)
are present. The regulation of TNFR1 is best known at the
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post-transcriptional level, namely the shedding of TNFR1 by TACE/
ADAM17 (Black et al, 1997). TNFR1 shedding and the resultant
acute decrease in the number of receptor molecules on the cell
surface might transiently desensitize cells to TNF action (Xanthoulea
et al, 2004). In addition, the pool of soluble TNFR1 generated by
shedding could function as a physiological attenuator of TNF activity
by competing for the ligand with the cell surface receptors (Aderka,
1996). In humans, mutations affecting TNFR1 shedding have been
linked with the development of TRAPS (TNF receptor-associated peri-
odic syndromes) (Huggins et al, 2004). Additionally, mice expressing a
non-sheddable TNFR1 are sensitive to TNF-induced and TNF-mediated
inflammation (Xanthoulea et al, 2004).
Glucocorticoids (GCs) are well-known anti-inflammatory mole-
cules that are strongly up-regulated by the hypothalamus-pituitary-
adrenaline axis (HPA) during inflammation as a negative-feedback
loop (Van Bogaert et al, 2011). GCs function by binding to the ubiqui-
tously expressed GC receptor, GR. Synthetic GCs such as dexametha-
sone (DEX) are effective against many inflammatory diseases and
against TNF-induced SIRS (Vandevyver et al, 2012b). The anti-
inflammatory mechanism of action of GCs has long been thought to
be based on direct inhibition of pro-inflammatory transcription
factors such as NF-jB. But recent work strongly indicates that forma-
tion of GC-stimulated GR dimers followed by gene induction is essen-
tial, thereby suggesting that GC/GR-induced genes (GRE genes)
perform anti-inflammatory actions (Vandevyver et al, 2012a). Several
GRE genes with anti-inflammatory functions have been described,
such as those coding for GILZ and MKP-1 (Pinheiro et al, 2013).
We previously demonstrated that the mouse strain SPRET/Ei (S)
displays an extreme and dominant resistance against TNF-induced
SIRS and that this trait is linked to a locus on proximal chromosome
2 and one on distal chromosome 6, the latter containing Tnfrsf1a
(Staelens et al, 2002). Here, we report that despite the sequence
variations in the S Tnfrsf1a gene, this TNFR1 is fully functional but
its expression is substantially weaker than in control C57BL6 (B)
mice. This difference is observed at the protein level, but not the
mRNA level. This trait is also linked to proximal chromosome 2 and
distal chromosome 6, suggesting a strong correlation between low
TNFR1 expression level and TNF resistance. The locus on chromo-
some 2 contains miR-511, which we here establish as a genuine
TNFR1 regulator, and which is significantly up-regulated in S mice.
We show that delivery of miR-511 to mice down-regulates TNFR1
protein and protects against TNF, as well as against endotoxic shock
and lethal hepatitis, and that anti-miR-511 up-regulates TNFR1 and
sensitizes for TNF, both in B and in S mice, breaking the resistance
of S mice to TNF. We also found that the TNF resistance of S mice is
completely dependent on the overactive HPA of these mice and that
the expression of miR-511 and, hence, TNFR1 is regulated by GCs.
We hypothesize that GCs protect against TNF-induced lethality partly
by induction of miR-511 and consequent down-regulation of TNFR1.
Results
SPRET/Ei mice have a low expression of a functional TNFR1
We previously showed that SPRET/Ei (S) mice, unlike C57BL/6 (B)
mice, are extremely resistant to lethal inflammatory shock induced
by TNF (Staelens et al, 2002). We confirm that the LD100 of a single
injection of TNF is > 500 lg in S mice and ~20 lg in B mice. Mice
resulting from a cross of B and S, (BXS)F1 mice, are also resistant
(Fig 1A). This resistance is linked to proximal chromosome 2
(0–40 cM with a peak at 15 cM) and distal chromosome 6
(40–70 cM with a peak at 46 cM). With this mapping resolution, the
gene encoding TNFR1, Tnfrsf1a (60.55 cM), is a probable candidate
resistance gene on the chromosome 6 locus (Staelens et al, 2002).
Sequence analysis showed that the TNFR1 proteins of S and B mice
differ by 10 AA (Supplementary Fig S1). By backcrossing the S
genome into a B background for 10 generations and selecting for the
distal part of chr6 using polymorphic markers located in and around
the Tnfrsf1a locus, and then intercrossing, we generated 99.9% B
consomic mice, harbouring 40 cM of distal chr6 with either two
copies of B Tnfrsf1a (B.S-chr6-BB), two copies of S Tnfrsf1a
A
B
Figure 1. Lethal response of different genotypes to increasing doses of
TNF and generation of consomic mice.
A Mice were injected with three different doses of TNF and mortality was
observed for 96 h. Ratios of deaths/total are displayed. Statistical
significance of the differences in survival was calculated relative to the B
group or the B.S.chr6 BB group. Student’s t-test using unpaired
comparisons and two-tailed analysis. ***P < 0.001 and ****P < 0.0001.
B Breeding scheme for the generation of B.S.chr6 consomic mice for the distal
part of chr6. After N10 generations of backcrossing, an intercross was
performed resulting in progenies carrying at least 40-cM-sized haplotypes
of B homozygosity (black), BS heterozygosity (green) or S homozygosity
(grey). The location of the Tnfrsf1a gene is indicated.
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(B.S-chr6-SS) or one copy of each (B.S-chr6-BS) (Fig 1B). None of
these mice showed any TNF resistance when injected with 20 lg
TNF, suggesting that the S TNFR1 protein is equally functional as
the B TNFR1 to induce lethal inflammation, when brought into a B
background (Fig 1A).
Low protein expression and normal mRNA of TNFR1 in S mice
To further investigate the genetic link between TNF resistance and
the distal chr6 locus, and because we had found that TNFR1+/
mice, expressing 50% TNFR1, are completely resistant to TNF over
a very large dose range (Van Hauwermeiren et al, 2013, 2014), we
measured TNFR1 protein in several tissues of B and S mice and
found that S mice express significantly less TNFR1 protein in all
tested organs (Fig 2A). This trait was dominant, and the biggest
difference from B levels was in the spleen. We also found reduced
soluble TNFR1 in the serum of S mice, ruling out increased shedding
of soluble TNFR1 in S mice. We confirmed the low TNFR1 protein
expression by measuring membrane-bound TNFR1 by FACS on
splenic neutrophils. Again, TNFR1 levels on S cells were signifi-
cantly lower than on B cells (Fig 2B). Furthermore, there was no
difference in TNFR1 protein level in the three types of consomic
mice, suggesting that the TNFR1 ELISA detected B and S TNFR1
equally well, that the lack of TNF protection of the consomic mice
was reflected in normal TNFR1 levels, and that the regulation of
TNFR1 protein levels is not regulated by distal chr6 in cis, but are
regulated in trans. However, measurement of TNFR1 mRNA levels
in B and S tissues by qPCR using conserved primers revealed no
differences (Fig 2C). To further confirm the relation between TNF
resistance and TNFR1 protein levels in S mice, we performed a new
BSB genetic backcross, generating 214 N2 mice, in which we
measured liver TNFR1 protein and performed genotyping using
polymorphic markers. Clear linkage with broad peaks was found
between low TNFR1 protein levels and proximal chr2 (0–40 cM)
and distal chr6 (40–70 cM) (Fig 2D). These are exactly the same
sub-chromosomal regions that were linked with TNF resistance
(P = 0.01 that both traits are linked to the same chromosomes). The
location of the gene encoding TNFR1 (Tnfrsf1a) on distal chromo-
some 6 (60.55 cM) suggests that both traits are associated mainly
with TNFR1 regulation. When studying epistatic interaction
between the chr6 and chr2 loci in terms of TNFR1 protein regulation
trait, we found (i) that the N2 mice with low TNFR1 protein level in
liver (< 300 ng/mg protein) that were BS heterozygous for distal
chr6 (D6Mit113), significantly more mice were BS on proximal chr2
(D2Mit359) (n = 50) than BB (n = 26) (P = 0.0487, chi2) and (ii)
that the N2 mice with high TNFR1 protein level in liver (> 300 ng/mg
protein) that were BB heterozygous for distal chr6 (D6Mit113),
significantly more mice were BB on proximal chr2 (n = 36) than BS
(n = 14) (P = 0.0241, chi2).
MiRNA-511 is a predicted TNFR1 regulator and is stronger
expressed in SPRET/Ei
The regulation of TNFR1 protein but not mRNA in trans could imply
miRNA-based regulation, and based on the linkage data, we hypoth-
esized that a miR on proximal chr2 might be involved. Using MiR
Walk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) and
the transcript Tnfrsf1a-001 (ENSMUST00000032491), we ran 10
different prediction programs and found a group of 18 miRs that
possibly target the Tnfrsf1a gene (Supplementary Fig S2). We found
two miRs on chr2, namely miR-296 (predicted only twice and
located distally on 97.9 cM) and miR-511 (predicted by 6 algorithms
and located at 10.5 cM). miR-511, located in intron 5 of the Mrc1
gene, has been suggested to be strictly co-expressed with Mrc1,
encoding the C type 1 mannose receptor (Squadrito et al, 2012). By
qPCR, we measured miR-511 and Mrc1 expression in liver (an
essential TNF target organ) and spleen (because the TNFR1 level
was very low in this organ) of naive B and S mice and found signifi-
cantly stronger expression of both RNAs in both organs of S mice
(Fig 3A). Analysis of the sequences of the mature miR-511 in B and
S revealed no differences. But comparison of the 30 UTR of the
Tnfrsf1a gene revealed two possible miR-511 target sequences, one
of which is identical between S and B and the other one showing
two nucleotide differences that interfere with the complementarity
with the miR-511 seed sequence (Fig 3B).
MiRNA-511 is a genuine TNFR1 regulator and has therapeutic
potential in mouse models
To study whether miR-511 is a genuine Tnfrsf1a regulator at the
30 UTR level in both B and S, we generated a reporter plasmid in
which the Renilla luciferase gene is controlled by the TNFR1
30 UTR. Co-transfection of HEK293T cells with pre-miR-511 and the
reporter plasmid significantly reduced luciferase expression after
48 h in both the B and S reporters (Fig 4A). Similarly, when B and S
MEF cultures were transfected with miR-511 and control miRs,
cellular TNFR1 protein levels were significantly reduced 24 h later
in both B and S MEFs (Fig 4B). Similar results were obtained using
primary hepatocytes of B and S (not shown). Furthermore, LNA-
locked anti-miRs specifically inhibiting miR-511 significantly up-
regulated TNFR1 in both B and S MEFs 24 h after transfection
(Fig 4C). We then evaluated whether miR-511 can regulate TNFR1
and the response to TNF in vivo. We injected pre-miR-511 under
control of the CMV promoter in mice using hydrodynamic tail vain
injection, which delivers plasmids to the liver (Liu et al, 1999). After
24 h, hepatic TNFR1 protein was measured, mice were injected with
20 lg TNF, and hypothermia and lethal shock were studied. miR-
511 injection led to a 20% reduction in TNFR1 protein expression,
and this reduction was associated with significant resistance to
TNF-induced hypothermia and mortality (Fig 4D). To study the
specificity and therapeutic potential of miR-511 in mice, we investi-
gated whether miR-511 could protect mice against LPS-induced
endotoxemia, a model in which TNF is centrally involved (Tracey
et al, 1988; Vandenbroucke et al, 2013). After hydrodynamic tail
vein injection of the miR-511-encoding plasmid, B mice were indeed
significantly protected against an LD50 of LPS, that is 200 lg/mouse
(Fig 4E). Because miR-511 was described as a regulator, under
certain conditions, of TLR4, the LPS receptor (Tserel et al, 2011),
we studied whether the protection provided by miR-511 against LPS
is mediated by TNFR1 regulation. We have shown before that
TNFR1 plays a role in LPS-induced lethal endotoxemia using TNFR1
KO mice (Vandenbroucke et al, 2013). Here, we studied the protec-
tive effect of miR-511 against an LD50 of LPS in TNFR1 KO mice,
that is 500 lg per mouse. As shown in Fig 4E, miR-511 did no
longer protect against LPS in the absence of TNFR1. Since TNF is
also an essential mediator in several forms of acute hepatitis
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Figure 2. Reduced TNFR1 protein levels in S mice and genetic linkage study of this trait.
A TNFR1 protein levels in serum and tissues of different mouse groups (n = 4–13). TNFR1 protein levels were measured by ELISA and compared to B, the levels of which
were set as 100% for each tissue. From left to right: B mice (black), TNFR1+/- mice (grey), (BxS)F1 mice (grey), S mice (grey); B.S-chr6-BB (black), B.S-chr6-SS (green)
and B.S-chr6-BS (grey).
B TNFR1 expression in splenic neutrophils of wild-type, TNFR1 KO and SPRET mice determined by FACS. Neutrophils were defined by flow cytometry (FACS) as
SSChighCD11b+Ly6GhighLy6Cmid and TNFR1+ cells from different strains were plotted in a histogram. In the insert, the median of TNFR1-PE signals were plotted and
this shows that SPRET mice have an intermediate TNFR1 expression compared to WT mice.
C TNFR1 mRNA levels measured by qPCR in organs of B (n = 3) and S (n = 4). Affymetrix microarray data from hepatocytes (Affy Mo Gene 1.0 ST Array).
D Backcross experiments in mice to determine genetic linkage between TNF resistance (left) and TNFR1 liver protein levels (right). QTL mapping of lethal response
(n = 178) was based on the data previously obtained and discussed by Staelens et al (2002), but the data were re-analysed in the current study using R/qtl software.
TNFR1 protein level in the liver of N2 mice (n = 214). For both TNF resistance and TNFR1 levels, the LOD scores show a QTL on chr2 (TNF resistance 15 cM,
LOD = 2.25 and TNFR1 levels 5 cM, LOD = 1.31) and chr6 (TNF resistance 46 cM, LOD = 3.11 and TNFR1 levels 70 cM, LOD = 4.15). Horizontal lines in the figures
represent LOD values that are suggestive (dots), significant (stripes) and highly significant (full line).
Data information: Data are presented as mean  SE. Student’s t-test using unpaired comparisons and two-tailed analysis. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.
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(Hasselblatt et al, 2007), we evaluated the therapeutic potential of
miR-511 in the concanavalin (ConA) model of acute, TNF-mediated
hepatitis (Hasselblatt et al, 2007). Twenty-four hours after hydrody-
namic pretreatment of mice with PBS, control miR or miR-511, mice
were injected with ConA, leading to TNF release, cell death (ALT
release) and hypothermia. Despite some minor effects of the control
miRs, miR-511 provided significant protection against ALT release
and hypothermia, without affecting the amount of TNF produced
(Fig 4F). These results suggest that TNFR1 reduction by miR-511
has protective effects in mouse models in which TNFR1 is
implicated.
To explore further whether miR-511 is linked with TNFR1
expression and the response to TNF, we delivered LNA-locked anti-
miRs by hydrodynamic injection to B mouse livers and studied
TNFR1 levels and TNF response 24 h later. miR-511-specific
anti-miR led to about 50% increase in expression of TNFR1 in livers
(Fig 5A), and to a significant sensitization of B mice to TNF as
measured by lethality and hypothermia (Fig 5A). Similar experi-
ments performed on S mice resulted in significant sensitization
towards an otherwise non-lethal dose of TNF in these mice, at the
level of both survival and hypothermia (Fig 5B). These data suggest
that inhibiting miR-511 leads to loss of the robust TNF resistance of
S mice. Similar data were obtained in TNF-resistant (BxS)F1 mice
(Supplementary Fig S3).
SPRET TNF resistance is dependent on miR-511 and on the HPA
We then analysed the regulation of miR-511 in mice. We have previ-
ously shown that S mice have an overactive HPA, producing high
basal levels of corticosterone (CS) and hence high basal levels of
A
B
Figure 3. miR-511 levels, sequence and target sequences in B and S mice.
A miR-511 and Mrc1 mRNA levels in liver (left panel) and spleen (right panel) in B (n = 5) and S (n = 5) mice. mRNA levels were measured by qPCR and levels detected
in B mice were set as 100%. Significance of the differences was studied by Student’s t-test, *P < 0.05. Data are presented as mean  SE.
B 30 UTR of the Tnfrsf1a gene of B mice. The single nucleotide polymorphisms (SNPs) found in the sequence of S mice are shown in red. miR-511 was predicted by the
program MicroSNiPer (http://cbdb.nimh.nih.gov/microsniper/) to have two target sequences, shown in bold and underlined. The most 30 target sequence contains two
nucleotide differences (in red) in S (lower blue panels) compared to B (upper blue panels), leading to different base pairing with miR-511, as shown in the lower
panel.
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Figure 4. miR-511 is a genuine regulator of TNFR1 and has therapeutic potential.
A Inhibition of Rluc activity of the psiCHECK-Tnfrsf1a-30UTR reporter plasmid with B sequence (black, left panel) and S sequence (grey, right panel) by miR-511
transfection in HEK-293T cells (n = 7–8).
B TNFR1 protein levels in B MEF cultures (black, n = 18) and S MEF cultures (grey, n = 24) 24 h after transfection with miR-511 or miR-CTR. TNFR1 protein levels were
measured in cell lysates by ELISA.
C TNFR1 protein levels in B MEF cultures (black, n = 18) and S MEF cultures (grey, n = 18) 24 h after transfection with anti-miR-511 or anti-miR-CTR. TNFR1 protein
levels were measured in cell lysates by ELISA.
D In vivo effect 24 h after hydrodynamic injection of B mice with plasmids expressing miR-511 (grey, n = 19), miR-CTR (black, n = 19) or PBS (black, n = 8). Liver TNFR1
protein levels (left panel) were measured by ELISA. Twenty-four hours after plasmid injection, mice were injected with 25 lg TNF. All mice pretreated with miR-511 (grey,
n = 12) survived, while 50% of the mice pretreated with miR-CTR (■, black, n = 12) or PBS (●, black, n = 12) died from TNF injection (middle panel). Twenty-four hours after
injection of TNF, body temperatures of mice pretreated with miR-511were significantly higher than those of the miR-CTR and PBS groups (right panel) (all groups n = 10).
E Survival of B mice and TNFR1/ mice injected with LPS, 24 h after miR-511 or miR-CTR hydrodynamic plasmid injection. B mice pretreated with miR-511 (grey,
n = 16) were significantly protected against 200 lg LPS compared to miR-CTR-pretreated mice (■, n = 15) or PBS-pretreated mice (●, n = 15) (left panel). No
difference in survival was found between TNFR1/ mice pretreated with miR-511 (grey, n = 11) or with miR-CTR (■, n = 9) against 500 lg LPS (right panel).
F Effect of hydrodynamic injection of plasmids expressing miR-511, miR-CTR or PBS on ConA-induced hepatitis in B mice (all groups n = 10). A total of 360 lg ConA
was injected i.v. 24 h after plasmids and 8 h later mice were analysed: liver damage (serum ALT levels, left panel); body temperatures of mice 8 h after ConA injection
(middle panel); TNF levels (right panel) 2 h after injection of ConA revealed similar concentrations of TNF in the three groups. miR-511-injected mice were
significantly protected in the ConA model.
Data information: Data are presented as mean  SE. Survival curves (Kaplan–Meyer plots) were compared by a log-rank test, and final outcomes were compared by a chi-square
test. Differences between groups were assessed by Student’s t-test using unpaired comparisons and two-tailed analysis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 5. Inhibition of miR-511 and GR sensitizes for TNF-induced SIRS.
A In vivo effect 24 h after hydrodynamic injection of B mice with plasmids expressing anti-miR-511 (n = 9), anti-miR-CTR (n = 9) or PBS (n = 10). TNFR1 protein levels
in the liver were measured by ELISA 24 h after hydrodynamic injection (left panel). Survival of B mice injected with 20 lg TNF, 24 h after hydrodynamic injection
(middle panel). Mice pretreated with anti-miR-511 (grey, n = 10) were significantly sensitized for TNF-induced SIRS compared to control groups and had the largest
drop in body temperature (right panel) 12 h after injection of 25 lg TNF.
B In vivo effect 24 h after injection of S mice with plasmids expressing anti-miR-511 (▲, n = 4), anti-miR-CTR (■, n = 4) or PBS (●, n = 4). Survival of S mice injected
with 400 lg TNF. Mice pretreated with anti-miR-511 were significantly sensitized for TNF compared to both control groups and showed the largest drop in body
temperature (right panel) of all groups.
C Inhibition of TNF resistance of S mice by RU486. B and S mice (all groups n = 5) were injected with 5 lg TNF (= LD100 in RU486-pretreated mice from preliminary
experiments), 30 min after injection of RU486 or DMSO control. Both B (black dashed line) and S mice (grey dashed line) pretreated with RU were significantly
sensitized for TNF lethality compared to DMSO/TNF controls (full lines) (top left panel) and for TNF-induced hypothermia measured 6 h after injection of 5 lg TNF.
IL-6 levels 6 h after injection of TNF were equally high in RU486-sensitized B and S mice. RU486 injection in S mice (n = 4) led to significantly increased TNFR1
protein expression in liver and spleen 6 h later compared to DMSO vehicle-treated S mice (n = 4).
D Two GRE elements (ConTra matrix M00205) were identified in the 50 region of the Mrc1 gene at 1,167 to 1,152 and 599 to 584 relative to the TSS. One GR half
binding site (ConTra matrix M00192) was found at 20 to 2 relative to the TSS.
Data information: Data are presented as mean  SE. Survival curves (Kaplan–Meyer plots) were compared by a log-rank test, and final outcomes were compared by a chi-square
test. Differences between groups were assessed by Student’s t-test using unpaired comparisons and two-tailed analysis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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numerous GR-inducible (GRE-element containing) genes (Dejager
et al, 2010). We here first validated the high basal HPA activity in S
compared to B mice (all groups n = 6) and measured CS in serum,
2 h after 10 lg TNF or 200 ll PBS. The obtained levels were
89.33  28.46 ng/ml (B, PBS), 377.83  153.15 ng/ml (B, TNF),
192.66  94.70 ng/ml (S, PBS) and 266.50  84.83 ng/ml (S,
TNF).
We investigated whether the TNF resistance of S mice depends on
the HPA by pretreating S mice with RU486, an irreversible inhibitor
of GR. The strong TNF resistance of S mice was completely abolished
when GR was blocked by RU486, and S and B mice became equally
sensitive, as measured by death from a low dose of 5 lg TNF, hypo-
thermia and release of the inflammatory mediator IL-6 (Fig 5C).
Furthermore, RU486 treatment of S mice led to significantly
increased expression of TNFR1 in liver and spleen (Fig 5C). These
data suggest that the TNF resistance of S mice depends entirely on
GR biological activity. Because we previously found, using GRdim
mice which express a GR that is poor in dimerization, that protection
by glucocorticoids (GCs) against TNF depends on GR dimerization
and induction of GRE-element containing genes (Vandevyver et al,
2012b), we investigated whether the mouse Mrc1 gene (of which
miR-511 is spliced out), contains GRE elements in its promoter. To
that end, we used the ConTra matrix (Hooghe et al, 2008) and found
two GRE elements and one GR half binding site (Fig 5D).
miR-511 and TNFR1 are GC-regulated
To study the dependency of expression of Mrc1 and miR-511 as well
as regulation of TNFR1 on GCs and GR, we adrenalectomized (Adx)
mice to remove the major source of GCs. We confirmed that Adx
significantly sensitizes mice for TNF-induced inflammation (Fig 6A)
(Bertini et al, 1988; Van Bogaert et al, 2011) and found that Adx
decreased the expression of several validated GRE genes (Tsc22d3,
encoding GILZ, and Dusp1, encoding MKP1) as well as Mrc1 and
miR-511 in the spleen and liver (Fig 6A) and also strongly increased
the expression of TNFR1 protein in these organs and in serum
(Fig 6A), supporting that Mrc-1 is a GRE gene and TNFR1 is under
control of GCs.
Synthetic GCs such as dexamethasone (DEX) are frequently used
as anti-inflammatory drugs, although there is still uncertainty about
the mechanisms of action. A low dose of 50 lg DEX protected against
TNF-induced lethal SIRS (Fig 6B), and significantly induced the
expression of several validated GRE genes, as well as Mrc1 and miR-
511 in liver and spleen (Fig 6B and C). Expression of TNFR1 mRNA
remained unchanged. In accordance with the induction of miR-511,
TNFR1 protein expression decreased significantly after DEX in both
organs and in the serum, suggesting that increased shedding of
sTNFR1 is not involved in the reduced tissue expression of TNFR1 by
DEX (Fig 6D). These data demonstrate that Mrc-1 and miR-511
increase and TNFR1 protein decrease depend on GCs and GR and
unfold a potential new mechanism of anti-inflammatory activity of
these steroids, namely via miR-511 induction and TNFR1 reduction.
Discussion
The mouse strain SPRET/Ei is derived from Mus spretus, which
diverged some 1.5 million years ago from the house mouse, Mus
musculus. The resulting genetic polymorphisms caused phenotypic
differences that are relatively easy to map by linkage analysis. The
SPRET/Ei (S) genome contains a SNP about every 100 bps
compared to the genomes of standard Mus musculus strains such as
C57BL/6J (B) (Dejager et al, 2009). S mice are extremely resistant
to TNF-induced SIRS, a trait that is dominant and linked to proximal
chr2 and distal chr6 (Staelens et al, 2002).
Because the Tnfrsf1a gene is centrally located in the critical
region on chr6, we investigated the basis of the genetic linkage of
TNF resistance to this gene. We found that S mice have 10 amino
acid changes in TNFR1 compared to B mice, but the S TNFR1 recep-
tor is fully functional when introduced in a B background. However,
the TNFR1 protein is expressed at 2- to 5-fold lower level in S than
in B mice, in serum and in all organs tested. Also, TNFR1 measured
by FACS on splenic neutrophils confirmed the low TNFR1
membrane expression in S mice. The low serum levels of TNFR1 in
S mice rule out that an extreme shedding of TNFR1 would for the
basis of the low cell and tissue expression of TNFR1 in these mice.
Thus, there is no qualitative but a quantitative link to TNFR1. In
previous work, we have shown that decreased TNFR1 expression
(50% in TNFR1+/ mice) leads to complete resistance to TNF-
induced SIRS in a non-linear gene-dosage way, meaning that 2×
reduction in TNFR1 protein leads to increased LD50 of > 40× (Van
Hauwermeiren et al, 2013) and this is linked with decreased TNF-
induced intestinal barrier dysfunction (Van Hauwermeiren et al,
2014). We here report that proximal chr2 and distal chr6 are linked
not only to the TNF resistance but also to the low TNFR1 protein
levels of S mice, suggesting that the low TNFR1 levels are responsi-
ble for the resistance. For TNFR1 levels, the LOD scores of chr6
were far beyond highly significant, while the chr2 LOD score was
only suggestive. With the poor breeding performance of interspecies
crosses such as those between B and S mice, only small backcross
populations could be obtained, leading to relatively broad peaks of
linkage and big critical regions of several tens of cM. In favour of
the data is the significant epistatic interaction between proximal
chr2 and distal chr6 both at the level of resistance against TNF
lethality (Staelens et al, 2002) and at the level of TNFR1 expression.
Furthermore, chr6 consomic mice could be generated but not chr2
consomics because of sterility problems, which occur frequently in
interspecies crosses (Dejager et al, 2009). The studies on chr6
consomic mice, however, led to the conclusion that regulation of
the TNFR1 locus on chr6 does not depend only on the locus itself,
but possibly also on the chr2 locus. Because the weak expression of
TNFR1 in S mice was observed only on the protein level and not the
mRNA level, its regulation by miRs was an interesting hypothesis,
especially since the regulation of TNFR1 remains very poorly
documented.
Over the past decade, miRs have emerged as important regula-
tors of mRNA stability and translation (Hausser & Zavolan, 2014).
Hundreds of miRs and their possible targets have been discovered
in the genomes of plants and animals (Bartel & Chen, 2004; Valencia-
Sanchez et al, 2006). Some miRs are essential as negative-feedback
molecules in inflammation and their anti-inflammatory effects have
been validated, such as miR-155 and miR-146a (Tsitsiou &
Lindsay, 2009). Most miRs bind to 30 UTRs of regulated mRNAs
and lead to faster degradation of mRNA, but many miRs can leave
the mRNA levels intact and inhibit translation. An example of the
latter is miR-579 (Han et al, 2013). We found that miR-511 was
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Figure 6. miR-511 expression depends on GCs.
A Adx significantly sensitizes B mice for TNF. Sham-operated mice (black, n = 12) all resisted 2 lg TNF while most Adx mice (grey, n = 12) succumbed to this dose of
TNF (top panel). Effect of adrenalectomy (Adx) on relative mRNA expression in the spleen of B mice (black, n = 5) and Adx mice (grey, n = 6). Bottom left panel shows
significant down-regulation of Tsc22d3 (encoding GILZ), Dusp-1 (encoding MKP-1), Mrc1 and miR-511 in Adx mice. Bottom right panel displays significant
up-regulation of the protein level of TNFR1 in liver, spleen and serum of Adx mice (grey) compared to control mice (black) (all groups n = 10).
B Pretreatment with 50 lg DEX protects B mice against lethal SIRS induced by 30 lg TNF (30 min, grey) compared to PBS pretreatment (250 ll, 30 min, black)
(both groups n = 13) (left panel). Relative mRNA expression in the liver of B mice 6 h after i.p. injection of PBS (black, n = 10) or DEX (grey, n = 10) (right panel).
Significant up-regulation of Tsc22d3, Sgk, Tat and Mrc1. Induction of miR-511 by DEX compared to PBS.
C Relative mRNA expression in the spleen of B mice 6 h after i.p. injection of PBS (black, n = 10) or DEX (grey, n = 10). Significant up-regulation of Tsc22d3, Sgk, Tat
and Mrc1. DEX had no effect on TNFR1 mRNA levels. Significant up-regulation of miR-511 by DEX.
D Significant down-regulation of the protein level of TNFR1 in liver (n = 20), spleen (n = 20) and serum (n = 5) by 50 lg DEX (grey) compared to PBS (black).
Data information: Data are presented as mean  SE. Survival curves (Kaplan–Meyer plots) were compared by a log-rank test, and final outcomes were compared by a chi-square
test. Differences between groups were assessed by Student’s t-test using unpaired comparisons and two-tailed analysis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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repeatedly predicted as a TNFR1 regulator by several algorithms,
that it is the only putative TNFR1 regulator located in the critical
region of chr2 and that it is expressed at significantly higher levels
in S than in B mice. miR-511 is located in an intron of the Mrc1
gene and was suggested to be regulated by the promoter of the
host gene (Squadrito et al, 2012). The Mrc1 gene is expressed
predominantly by macrophages (Squadrito et al, 2012), but also by
liver, lymph nodes and spleen (Supplementary Fig S5). In agree-
ment with Mrc1/miR-511 co-regulation, we found higher Mrc1
mRNA levels in S than B liver and spleen. We also found that
miR-511 indeed regulates the TNFR1 30 UTR in a reporter system,
that transfection of this miR down-regulates TNFR1 protein in
B and S primary fibroblasts moderately and that anti-miRs have
the inverse effect.
Interestingly, transient in vivo delivery of miR-511 down-
regulated TNFR1 in livers of mice and protected them not only
against TNF, but also against endotoxic shock (in a TNFR1-dependent
way) and in a model of TNF-mediated lethal hepatitis (induced by
ConA). The experimental delivery system of the miRs and anti-
miRs targets only the liver of mice (Liu et al, 1999), and hence the
effect of liver-specific regulation of TNFR1 on the lethal response
to TNF is interesting. Remarkably, a modest decline in TNFR1
protein expression by miR-511 was able to protect the mice against
TNF. This is in line with the extreme non-linear gene-dosage effect
we described recently (Van Hauwermeiren et al, 2013). Also, the
liver-specific down-regulation of TNFR1 via hydrodynamic tail
injection suffices to protect against TNF-induced lethal shock,
suggesting that liver TNFR1 plays an important role, and this is in
line with our previous findings (Van Bogaert et al, 2011). Finally,
we opted for the ConA model and not for the well-known TNF +
galactosamine model, because in the latter model, only weak
effects of partial TNFR1 concentration changes were found (Van
Hauwermeiren et al, 2013). Our findings indicate miR-511 is a
genuine TNFR1 regulator and has therapeutic potential, at least in
mice. Optimization of therapy with miR-511 by more general deliv-
ery and safety of this therapy should be addressed in the future.
Furthermore, the miR-511-TNFR1 axis has yet to be validated in
humans. In Supplementary Fig S6, we display the high sequence
similarity of the mouse (C57BL6) and human miR-511 seed
sequence and two TNFR1 target sequences. Also, anti-miRs inhibit-
ing miR-511 delivered specifically in the liver of mice increased
TNFR1 expression and sensitized them for TNF-induced SIRS.
Since also S mice were sensitized by this anti-miR delivery, we
propose that at least part of the extremely robust TNF resistance
of S mice depends on miR-511. Final proof that miR-511 is respon-
sible for part of the TNF resistance and low TNFR1 protein levels
of S mice should come from genetic disruption of this miR-511,
but genetic manipulation of S mice has not been possible so far
despite intense efforts (Hochepied et al, 2004). Finally, in silico
prediction of other targets of miR-511, using miR Walk, revealed
no less than 997 targets which are predicted by at least 4/10
programs, including some that are important players in the TNF
and LPS signalling pathways, that is TRAF2 (Supplementary Fig
S2B).
The genetic link of TNF resistance and low TNFR1 levels to chr2
and chr6 is difficult to explain. We found only minimal changes in
the miR-511 target sequence between B and S in the Tnfrsf1a 30 UTR,
and both these sequences responded equally well to transfected
miR-511. One possibility is that subtle differences in the entire
TNFR1 mRNA sequence may cause better response of the S Tnfrsf1a
gene to miR-511 because of different 3D mRNA structure. Further-
more, it is not easy to explain the linkage to the miR-511 locus if the
sequence of miR-511 appears to be identical in B and S mice. It is
clear that we observe higher expression of Mrc1 and miR-511 in S
than in B tissues. We previously found that S mice have an over-
active HPA, which is stimulated by stress and leads to ACTH release
from the pituitary and corticosterone (CS) release from adrenals. In
S mice, high CS levels lead to high basal expression levels of GR-
induced genes (Dejager et al, 2010). GR can homodimerize and act
as a true transcription factor, binding to GRE-like elements and
strongly inducing gene expression. The canonical GRE element
resembles AGAACA(N)3TGTTCT. Such elements can be found near
transcription start sites of GRE genes (Wiench et al, 2011). Typical
GRE genes are involved in gluconeogenesis (Sgk, Tat) or have anti-
inflammatory effects (Tsc22d3, Dusp1). Using GRdim mice, which
express a mutant GR that is poor in dimerization, it was recently
shown that GR dimerization followed by GRE-gene induction is
essential in its protection against SIRS (Kleiman et al, 2012;
Vandevyver et al, 2012b). Interestingly, inhibition of GR by the irre-
versible inhibitor RU486 sensitized both B and S mice to TNF, but
also led to complete loss of differences in TNF response between B
and S, which means that the spectacular TNF resistance of S mice
totally depends on their overactive HPA. We believe that our data
indicate that both phenotypes (low TNFR1 protein and TNF resis-
tance) depend on the HPA but are linked with a downstream GRE
gene, relevant in this model and that mediates the anti-inflamma-
tory effect of GR, and is located on proximal chr2, namely the Mrc1/
miR-511 locus. We indeed found that: (i) treatment of S mice with
RU486 led to increased TNFR1 protein levels and increased TNF
sensitivity, (ii) removal of adrenals in mice markedly reduced the
basal expression levels of Mrc1 and miR-511 and increased TNFR1
levels and TNF sensitivity, (iii) injection of DEX (a synthetic GC) in
mice led to induction of these genes and to reduction of TNFR1
protein expression in tissues and in the serum (thus in a shedding
independent way), (iv) that the induction of miR-511 and reduction
of TNFR1 protein is not observed in GRdim mice (data not shown)
and (v) in the promoter of the Mrc1 gene, we found GRE elements,
and Mrc1 was proven to be induced by GCs (Ehrchen et al, 2007).
GCs have been shown to acutely inhibit miR processing enzymes
such as Drosha and Dicer (Smith et al, 2010), but also to induce
miRs in several cell systems (Izzotti et al, 2010; Smith et al, 2013).
Our data suggest that in S mice, an overactive HPA leads to high
expression of miR-511 and hence strong down-regulation of TNFR1
protein expression and less response to TNF. Hence, GCs, either
endogenous or therapeutically administered, are clearly able to
induce miRs that could inhibit pro-inflammatory targets.
A new regulatory network important in TNF biology is appear-
ing from our studies. We show that miR-511 is strongly induced by
GCs and is a true TNFR1 modulator and thus an anti-inflammatory
miR. Since minimal reductions of TNFR1 have considerable effects
on TNF sensitivity (Van Hauwermeiren et al, 2014), we believe
that at least part of the anti-inflammatory effects of GCs are
mediated by induction of this miR, resulting in reduced TNFR1
expression. Further studies are needed to determine whether this
anti-inflammatory system encompasses other inflammatory media-
tors and targets.
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Materials and Methods
Mice
C57BL/6J (B) mice were purchased from Janvier-Europe. SPRET/
Ei (S) mice were obtained from The Jackson Laboratory and bred
in our facility. (BXS)F1 mice were generated by crossing female B
mice with male S mice. B.S.chr6 consomic mice were generated by
backcrossing (BxS)F1 mice with the host strain, B, and then
repeatedly backcrossing to the host strain and screening the prog-
eny for the non-recombined S donor locus of interest (Tnfrsf1a) in
each generation (Nadeau et al, 2000). B.S.chr6 consomic mice
heterozygous for the S Tnfrsf1a allele were intercrossed at the N10
generation, and resulting N10F2 mice homozygous for the B
Tnfrsf1a allele and mice homozygous for the S Tnfrsf1a allele and
heterozygotes were identified by typing for the polymorphic mark-
ers around the Tnfrsf1a gene. TNFR1/ mice generated by Dr. M.
Rothe (Rothe et al, 1993) were a kind gift from Dr. H. Bleuthmann.
TNFR1+/ mice were generated by crossing TNFR1/ mice with
B mice. Adrenalectomized B mice were purchased from Janvier-
Europe and received 0.9% NaCl in their drinking water. GRdim
mice and the WT controls had an FVB background and were
described before (Vandevyver et al, 2012b). All mice were kept in
individually ventilated cages under a constant dark–light cycle in a
conventional animal house and received food and water ad libitum.
The mice were used at the age of 8–12 weeks and were all female.
Animal experiments were approved by the institutional ethics
committee for animal welfare of the Faculty of Sciences, Ghent
University, Belgium. Genome sequences of SPRET/Ei were
retrieved from the Sanger Laboratories ftp://ftp-mouse.sanger.ac.uk/
current_snps/mgp.v3.snps.rsIDdbSNPv137.vcf.gz.
Compounds, injections and measurements
Recombinant mouse TNF (specific activity of 1.66 × 109 IU/mg)
was expressed in Escherichia coli and purified in our laboratory.
The preparation contained less than 6 EU/mg protein of endo-
toxin as determined by a Limulus amoebocyte lysate assay and
had a concentration of 1 mg/ml. Lipopolysaccharide (LPS) from
Salmonella abortus equii, RU486 and ConA were purchased from
Sigma. RU486 was dissolved in DMSO and 5 mg was injected in
50 ll DMSO per mouse. DMSO was used as solvent control.
Dexamethasone was bought as a ready-to-inject solution called
Rapidexon from Medini N.V. and injected i.p. at 50 lg/mouse.
On one occasion, for the induction of Mrc1 in B mice, 500 lg
Rapidexon was injected. Mice were injected intraperitoneally with
TNF or LPS in 0.3 ml of pyrogen-free phosphate-buffered saline
(PBS). Mortality was recorded regularly until no further deaths
occurred. Rectal body temperatures were measured with an elec-
tronic thermometer from Comark. Concanavalin A (360 lg in
200 ll per mouse) was injected intravenously. Two hours later,
100 ll of blood was withdrawn from the retro-orbital plexus for
serum TNF detection. Six hours later, another blood sample was
taken, and serum alanine aminotransferase (ALT) was measured
using a Hitachi kit and apparatus in the Clinical Biology Labora-
tory of Ghent University Hospital. The bio-activity of TNF in the
serum was measured with an MTT cell death assay using the
sensitive L929 cell line. Serum IL-6 was measured using a specific
bio-assay based on the proliferating effect of IL-6 on 7TD1 hybrid-
oma cells.
Tnfrsf1a 30 UTR reporter construct and luciferase reporter assay
The DNA coding for the Tnfrsf1a 30 UTR of B and S was purchased
from Genscript. The 514-bp sequence of B and the 508-bp sequence
of S were digested out of the vector pUC57 with SgfI and NotI and
ligated in the psiCHECK-2 vector (Promega). The constructs were
transformed into MC1061 cells, and transformants were screened
for the presence of a correct sequence by using PCR primers CAGAT
GAAATGGGTAAGTAC and AAACCCTAACCACCGCTTAA. The 30 UTR
reporter plasmids were co-transfected with pre-miR precursor mole-
cules (Supplementary Fig S4) in HEK-293T cells using Lipofectamine
2000 (Invitrogen). Cells were harvested 48 h post-transfection,
washed with PBS and lysed in passive lysis buffer (PLB). Firefly
luciferase activity was measured in Optiplate-96 F plates (Perkin
Elmer) by adding Luciferase Assay Reagent II (Promega) to generate
a luminescent signal. This signal was quantified using the GLOMAX
96 microplate luminometer (Promega). Afterwards, this reaction
was quenched, and the Renilla luciferase reaction was initiated by
adding Stop & Glo Reagent (Promega) to the same wells.
Hydrodynamic injection in mice
A precursor miRNA expression clone for mmu-miR-511 (GAUACCC
ACCAUGCCUUUUGCUCUGCACUCAGUAAAUAAUAAUUUGUGAAU
GUGUAGCAAAAGACAGGAUGGGGAUCCA), cloned in the pEZX-
MR04 vector, was purchased from GeneCopoeia, as well as a
scrambled control clone (Supplementary Fig S4). LNA-enhanced
miRCURY i-mmu-miR-511-5p (GAGTGCAGAGCAAAAGGCA) and
i-miR-511-5pMMControl were purchased from Exiqon (Supplementary
Fig S4). Plasmid DNA was dissolved in PBS, and 10 lg in a volume
of 2 ml was injected in the tail vein under high pressure. This tech-
nique guarantees hepatocyte-specific uptake and transient expres-
sion of the plasmid (Liu et al, 1999).
mTNFR1 ELISA and CS ELISA
Liver, kidney, lung and spleen of mice were excised and snap-frozen
in liquid nitrogen. Samples were homogenized in PBS containing
0.5% CHAPS and complete protease inhibitor cocktail tablets from
Roche. Homogenates were centrifuged for 30 min at 20,000 g and
4°C, after which the supernatant was collected and stored at 80°C.
Blood was collected by retro-orbital bleeding and allowed to clot for
1 h at 37°C. Serum was prepared and stored at 20°C. Protein
concentration was determined by the Bradford method (Bio-Rad),
and 500 lg was used to perform an ELISA specific for TNFR1 using
the mouse sTNF RI/TNFRSF1A duoset ELISA from R&D Systems.
The levels were normalized to the levels of C57BL/6 or control
samples, which were set as 100%.
CS was measured in serum using an ELISA (ARBOR Assays) as
suggested by the manufacturer.
FACS measurement of TNFR1 on neutrophils of mice
Spleens were harvested from untreated wild-type, TNFR1 KO and
SPRET mice, and single cells were obtained by teasing the spleen
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apart by pressing it through a 100-lm cell strainer, eliminating
clumps and debris. Cells were collected in 10 ml DPBS and were
spin down (4°C, 7 min, 400× g). Cells were lysed with 1 ml of lysis
buffer (8.3 g NH4Cl, 1 g KHCO3 and 200 ll 0.5 mol/l EDTA),
washed and counted. A total of 1 × 106 splenocytes were stained for
30 min at 4°C in the dark with the following anti-mouse antibodies:
anti-TCRb-FITC, anti-CD19-PECy7, anti-CD11b-Pacific Blue, anti-
Ly6C-APC, anti-Ly6G-AF700 (all from BD Biosciences) and anti-
TNFR1-PE (BioLegend). Cells were washed and dissolved in FACS
buffer. Fluorescent events were acquired using an LSR2 and analy-
sed using FACSDiva software (BD Biosciences). Neutrophils were
defined as SSChighCD11b+Ly6GhighLy6Chigh. After gating neutrophils
(see Supplementary Fig S7), TNFR1+ cells were plotted in a histo-
gram. The correct neutrophil population and TNFR1+ populations
were gated using an FMO conditions without anti-Ly6G-AF700 and
anti-TNFR1-PE antibodies, respectively. Analysis was performed
using FlowJo software (Tree Star, Inc.)
qPCR
Liver, kidney, lung and spleen samples were stored in RNA later
from Ambion. Samples were homogenized and RNA was extracted
using an RNeasy mini kit from Qiagen. RNA concentration was
measured with the NanoDrop1000 from ThermoScientific, and
500 ng RNA was used to prepare cDNA with iScript from Bio-Rad.
qPCR was performed using the SYBR Green master mix and the
LightCycler 480 from Roche with the following primers: 50-
CCGGGAGAAGAGGGATAGCTT-30 and 50-TCGGACAGTCACTCACC
AAGT-30 for mTNFR1, 50-GCTGAATCCCAGAAATTCCGC-30 and 50-A
TCACAGGCATACAGGGTGAC-30 for Mrc1, 530 and 50-TCGGACAGT-
CACTCACCAAGT-30 for mTNFR1, 50-GCTGAATCCCAGAAATTC-
Gilz, 5z, 5 5 5z, 5, 5 CGGACAGTCA and 5 and 5, 5 CGGACAGTCAC
TCACCA for CGC-3 and 5 and 5, 5 CGGACAGTCACTCAC for Mrc1,
50-TGAAGCAGGCATCTGAGGG-30 and 50-CGAAGGTGGAAGAGTGG-
GAG-30 for Gapdh, and 50-CCTGCTGCTCTCAAGGTT-30 and 50-TGGC
TGTCACTGCCTGGTACTT-30 for Rpl13a. The best performing
housekeeping genes were determined with geNorm (Vandesompele
et al, 2002). No SNPs between C57BL/6 and SPRET/Ei were
included in the primers (not shown). qPCR for miR-511 was done
using specific MultiScribeTM cDNA synthesis and TaqMan Pri-
miRNA Assays for mmu-miR-511 and three stable miRs (mmu-miR-
194, mmu-miR-24 and mmu-miR-29a from Applied Biosystems). All
values shown are relative expression values normalized to the
geometric mean of the selected housekeeping genes.
Quantitative trait loci (QTL) mapping
To map the loci responsible for low TNFR1 protein levels in S mice,
an interspecies backcross between female (C57BL/6 × SPRET/Ei)
F1 mice and male C57BL/6 mice was set up and N2 backcross mice
were generated. Tail biopsies were collected at weaning from
214 N2 mice, and high-quality genomic DNA was prepared by
standard phenol–chloroform extraction. A genome scan on 100 ng
DNA was performed with 72 microsatellite markers. Primer
sequences from the Massachusetts Institute of Technology (MIT)
were retrieved from www.informatics.jax.org. Coverage of the
genome was estimated by taking the position of the marker loci on
the Mouse Genome Database genetic map obtained from The
Jackson Laboratory and applying a swept radius of 20 cM (Silver,
1995). Livers from the 214 N2 backcross mice were excised at the
age of 8 weeks and snap-frozen in liquid nitrogen. Total protein
was isolated and 500 lg was used to measure TNFR1 levels by
ELISA. After the first screening, the density of markers was
increased on chromosomes 2 and 6, which were shown to be linked
to the trait. Linkage analysis was performed using the R/qtl software
version 1.12-26 running under R 2.9.1 (Broman, 2003). Significance
thresholds of LOD scores were estimated by 10,000 permutations of
experimental data. For TNF resistance, the 5% significance thres-
hold LOD score is 2.50, the 10% threshold is 2, and the suggestive
level is 1.4. For TNFR1 protein levels, the 5% significance threshold
LOD score is 2.41, the 10% threshold is 2.12, and the suggestive
threshold is 1.34. The protein level was analysed using a normal
model by the EM algorithm in R/qtl (Lander & Botstein, 1989).
Mouse embryonic fibroblast (MEF) studies
MEFs were isolated from embryos 18 days post-coitum. They were
cultured in DMEM medium (supplemented with 10% FCS, penicil-
lin, streptomycin, sodium pyruvate and L-glutamine) and seeded in
culture flasks. Cells were trypsinized and seeded in 24-well plates at
100,000 cells per well. Pre-miRTM miRNA Precursors for mmu-mir-
511 (GAUACCCACCAUGCCUUUUGCUCUGCACUCAGUAAAUAAUA
AUUUGUGAAUGUGUAGCAAAAGACAGGAUGGGGAUCCA) and a
negative control were purchased from Ambion (Supplementary Fig
S4). LNA-enhanced miRCURY i-mmu-miR-511-5p (GAGTGCAGAGC
The paper explained
Problem
Sepsis is an acute inflammatory condition resulting from infection. It
is a huge unmet medical need and highly lethal. Worldwide at least
20 million people suffer from sepsis each year. Several key molecules
in sepsis have been identified. One of them is tumour necrosis factor
(TNF). But numerous clinical trials inhibiting TNF have not resulted in
a solid new therapy based on TNF inhibition.
Results
We believe that the major TNF receptor, TNFR1, which is ubiqui-
tously expressed, is a good and more specific therapeutic target for
sepsis. We have found a mouse strain, SPRET/Ei, which is very resis-
tant to TNF-induced acute, lethal inflammation. This trait appears
to result from a very low expression of the TNFR1 protein, and this
in turn is under the control of a microRNA, namely miR-511. We
validate miR-511 as a true TNFR1-regulating miR, which can be
delivered to mice and then reduces the TNFR1 levels and protects
mice in the TNF and other mouse inflammation models. Further-
more, this miR-511 is strongly induced by glucocorticoids, which
are the standard first-line anti-inflammation therapeutics. Thus,
our work also uncovers a novel anti-inflammatory pathway of
glucocorticoids.
Impact
Although therapeutic use of microRNAs is a hotly debated issue, our
data show that microRNA delivery to a mammalian organism (mouse)
can down-regulate the TNFR1 protein expression. Whether that result
can also be translated to humans is not yet known, and whether
that effect has off-target effects is also unknown so far. But the
data underline that TNFR1 is an interesting drug target in acute
inflammation.
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AAAAGGCA) and i-miR-511-5pMMControl were purchased from
Exiqon. Fifty micromoles of the molecules was transfected using
Lipofectamine RNAiMAX from Invitrogen, and 24 h later the cells
were lysed with PBS containing 0.5% CHAPS and complete protease
inhibitor cocktail tablets from Roche. TNFR1 was measured using
the TNFR1 ELISA.
ConTra analysis of Mrc1 promoter
Analysis of the 2000-bp upstream Mrc1 promoter for GRE sequences
across species was conducted using the ConTra online software
(Hooghe et al, 2008), with the highest stringency of core = 1.00 and
similarity matrix = 0.95 and a method to minimize false positives
with TRANSFAC matrices. (http://bioit.dmbr.ugent.be/contrav2/
cite_newstyle.php).
Statistical analysis
Survival curves (Kaplan–Meyer plots) were compared by a log-rank
test, and final outcomes were compared by a chi-square test. Data are
expressed as the means  SE. Statistical significance of differences
between groups was evaluated with Student’s t-tests using unpaired
comparisons and two-tailed analysis. Error bars in the figures
represent the mean  SE *, **, *** and **** represent P < 0.05,
P < 0.01, P < 0.001 and P < 0.0001, respectively. The relevant, exact
P-values are summarized in Supplementary Fig S8.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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